Novel 5-HT Neurotherapeutic Programs
Psychiatric & Neurological Disorders (e.g., Depression, PTSD)
Key Facts
About Xylo
Xylo is a private, preclinical-stage biotech developing a novel class of small-molecule neuroplastogens, or psychedelic-inspired therapeutics, designed to promote neuroplasticity without the hallucinogenic effects associated with classical psychedelics. The company combines computational drug design and advanced neuroscience to target specific serotonin receptors, aiming to create accessible, next-generation treatments for major psychiatric conditions. Following a rebrand from Psylo and an $8 million Series Seed financing in 2024, Xylo has established a US corporate structure and is building a pipeline focused on precision neurotherapeutics. Its experienced team and distinguished scientific advisory board position it to advance its programs toward clinical development.
View full company profile